Log in

190A Chordia Therapeutics Inc. TSE · Japan

Chordia Therapeutics (190A) news

Chordia Therapeutics Inc. is a public biotech or pharmaceutical company listed on TSE under the ticker 190A, recorded under Japan. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Chordia Therapeutics news

We have not published a story on Chordia Therapeutics yet. When there is news, it will appear here.

Questions about Chordia Therapeutics

What is the ticker symbol of Chordia Therapeutics?

Chordia Therapeutics Inc. trades under the ticker 190A on TSE.

Where is Chordia Therapeutics listed?

Chordia Therapeutics Inc. is listed on TSE.

Which country or territory is Chordia Therapeutics listed under?

Our directory records Chordia Therapeutics Inc. under Japan.

What does Chordia Therapeutics do?

Our directory classifies Chordia Therapeutics Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Chordia Therapeutics?

The ISIN recorded for Chordia Therapeutics Inc. is JP3283730004.

Does aibio.space cover Chordia Therapeutics?

aibio.space lists Chordia Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Chordia Therapeutics?

Companies in our directory listed in the same country and business area as Chordia Therapeutics: JCR Pharmaceuticals Co., CellSource Co., Zeria Pharmaceutical Co., Sumitomo Pharma Co.Ltd., Pharmarise Holdings, Elan.

Investor discussion: Chordia Therapeutics

Members talk about Chordia Therapeutics (190A). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open TSE:190A on TradingView.

Listing details

Chordia Therapeutics Inc. is a public biotech or pharmaceutical company listed on TSE under the ticker 190A, recorded under Japan. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Chordia Therapeutics Inc.
Ticker
190A
Listing
TSE
Country or territory
Japan
Business scope
Pharmaceuticals: Major
ISIN
JP3283730004
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.